Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC1 vs WOKVAC vaccines for HER2+ breast cancer recurrence
NCT03384914Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2018
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of DC1 and WOKVAC in breast cancer, sponsored by Moffitt Cancer Center. Started Feb 2018; status: active, not recruiting.
02
Drugs
DC1WOKVAC
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03384914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384914.